Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Want to see AMRN full AI Analyst Report?
Top Page
Amarin
(NASDAQ:AMRN)
Select Model
Select Model
Rating:56Neutral
Price Target:
$15.00
▲(0.13% Upside)
Action:Reiterated
Date:05/16/26
The score is held back primarily by continued unprofitability and a negative P/E (valuation headwind), despite a strong balance sheet and improving cash generation. The latest earnings call was a notable positive (cost savings trajectory, guidance for 2026 cash-flow positivity, and international traction), while technicals appear mostly neutral and the AGM outcome adds a modest operational constraint.
Positive Factors
Balance sheet strength / low leverage
Amarin's minimal debt, sizable cash balance and large working capital create a durable financial runway to fund operations, support international launches, and absorb R&D or legal costs. Low leverage reduces bankruptcy risk and preserves strategic optionality during multi-year commercialization cycles.
Negative Factors
Persistent unprofitability
Despite recent revenue recovery, continued net losses and negative margins limit internal capital for growth and depress returns on equity. Structural unprofitability increases sensitivity to revenue shocks and could force sustained cost cuts or external financing if cash generation falters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength / low leverage
Amarin's minimal debt, sizable cash balance and large working capital create a durable financial runway to fund operations, support international launches, and absorb R&D or legal costs. Low leverage reduces bankruptcy risk and preserves strategic optionality during multi-year commercialization cycles.
Read all positive factors
Amarin (AMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$304.00M
Dividend YieldN/A
Average Volume (3M)72.50K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth1.40%
EPS Growth62.01%
CountryUS
Employees275
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.54
Shares Outstanding20,969,109
10 Day Avg. Volume43,751
30 Day Avg. Volume72,500
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.81
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda-77.20
Forecast
1Y Price Target
$12.00Price Target Upside-19.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)$174.40M
Amarin Business Overview & Revenue Model
Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead ...
How the Company Makes Money
Amarin makes money primarily by selling its prescription product icosapent ethyl under the brand names VASCEPA (U.S.) and VAZKEPA (in certain non-U.S. markets). Revenue is generated when wholesalers, pharmacies, hospitals, and other customers purc...
Amarin Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed clear operational progress: revenue growth, meaningful expense reductions, improved operating losses, second consecutive quarter of positive operating cash flow, a strong cash position with no debt, and accelerating international traction via the Recordati partnership. Offsetting risks include materially higher COGS in the near term (62% YoY increase), quarter-to-quarter revenue variability from the partnered model, ongoing U.S. generic competition risk, and remaining restructuring charges. On balance, the positive developments (cash generation, cost savings, market-share gains, favorable guideline positioning, and international rollout momentum) outweigh the near-term headwinds.Positive Updates
Revenue Growth and Top-Line Metrics
Total net revenue rose to $45.1 million in Q1 2026 from $42.0 million in Q1 2025, an increase of approximately 7.4% year-over-year. U.S. revenue was broadly consistent with Q1 2025. The overall IPE market grew ~3% YoY in Q1 2026.
Negative Updates
Higher Cost of Goods Sold and Margin Pressure
Cost of goods sold increased by $10.5 million, or 62% YoY, reflecting higher product volumes from regaining an exclusive PBM relationship in the U.S. and supply shipments to international partners. Management expects elevated COGS to continue until Q3 2026 (anniversary of regaining exclusivity), contributing to quarter-to-quarter margin variability.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Top-Line Metrics
Total net revenue rose to $45.1 million in Q1 2026 from $42.0 million in Q1 2025, an increase of approximately 7.4% year-over-year. U.S. revenue was broadly consistent with Q1 2025. The overall IPE market grew ~3% YoY in Q1 2026.
Read all positive updates
Company Guidance
Management guided that Amarin is on track to deliver roughly $70 million of annualized operating expense savings by June 30, 2026, expects to generate positive cash flow for full-year 2026 (having reported two consecutive quarters of positive operating cash flow, $6.4 million in Q1), and finished Q1 with $308 million in cash and investments (up from $303M at year-end), no debt and $450 million of working capital. They said they expect to maintain key U.S. payer exclusives through the end of 2026 (supporting NSP stability), warned that cost of goods sold — which rose $10.5 million (62%) in Q1 — will remain elevated through Q3 2026 due in part to regained exclusives and supply shipments, and noted restructuring is largely complete (Q1 restructuring $3.3M, total to date $39.6M with only nominal remaining in Q2). Financially, total net revenue was $45.1 million in Q1 (vs. $42.0M a year ago), operating expenses fell 31% to $29.1M (ex-restruct $25.8M, -38% YoY), SG&A declined 42% to 47% of net sales (vs. 87% prior year), operating loss narrowed to $11.3M (ex-restruct $8.0M), and management highlighted strong early partner-driven international traction (Europe product revenue $4.9M in Q1, +113% sequentially from $2.3M in Q4, including $3.0M supply shipments to Recordati; Rest of World $2.8M).Amarin Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 214.88M | 213.65M | 228.61M | 306.91M | 369.19M | 583.19M |
| Gross Profit | 112.77M | 120.87M | 81.38M | 165.54M | 242.48M | 461.86M |
| EBITDA | -2.26M | -33.01M | -74.18M | -50.70M | -100.69M | 14.28M |
| Net Income | -33.61M | -38.80M | -82.18M | -59.11M | -105.80M | 7.73M |
Balance Sheet | ||||||
| Total Assets | 645.76M | 670.77M | 685.35M | 831.68M | 886.18M | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 307.82M | 302.79M | 294.22M | 320.66M | 309.36M | 454.13M |
| Total Debt | 5.58M | 12.16M | 7.72M | 8.74M | 10.02M | 8.58M |
| Total Liabilities | 196.35M | 211.49M | 199.17M | 279.59M | 290.85M | 400.97M |
| Stockholders Equity | 449.41M | 459.28M | 486.18M | 552.10M | 595.33M | 667.10M |
Cash Flow | ||||||
| Free Cash Flow | 25.51M | 6.74M | -31.02M | 6.88M | -179.98M | -66.53M |
| Operating Cash Flow | 25.51M | 6.74M | -31.03M | 6.91M | -179.98M | -66.53M |
| Investing Cash Flow | -11.72M | 8.85M | -45.98M | -25.62M | 175.18M | 104.09M |
| Financing Cash Flow | -2.59M | -2.04M | -1.44M | 230.89K | -378.77K | -5.07M |
Amarin Technical Analysis
Neutral
14.98
Price Trends
14.54
Negative
14.82
Negative
15.44
Negative
Market Momentum
-0.05
Positive
49.55
Neutral
53.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Neutral. The current price of 14.98 is above the 20-day moving average (MA) of 14.55, above the 50-day MA of 14.54, and below the 200-day MA of 15.44, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 49.55 is Neutral, neither overbought nor oversold. The STOCH value of 53.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMRN.
Amarin Risk Analysis
Amarin disclosed 65 risk factors in its most recent earnings report. Amarin reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amarin Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $564.13M | 1.54 | 147.03% | ― | 47.61% | 854.73% | |
57 Neutral | $593.15M | -4.17 | -42.57% | ― | 80.00% | 25.18% | |
56 Neutral | $304.00M | -8.97 | -7.34% | ― | 1.40% | 62.01% | |
52 Neutral | $1.04B | -25.29 | -38.92% | ― | ― | 17.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $335.22M | -1.64 | -70.79% | ― | ― | 28.56% | |
42 Neutral | $105.56M | -3.86 | >-0.01% | ― | ― | 53.00% |
* Healthcare Sector Average
AMRN
Amarin
14.49
2.75
23.42%
ALT
Altimmune
3.05
-2.25
-42.45%
RIGL
Rigel
30.49
10.34
51.32%
ALDX
Aldeyra Therapeutics
1.75
-0.37
-17.45%
RCKT
Rocket Pharmaceuticals
3.07
0.30
10.83%
CRVS
Corvus Pharmaceuticals
12.41
8.38
207.94%
Amarin Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Amarin Shareholders Reject Dilution, Governance Proposals at AGM
Negative
May 15, 2026
At its May 13, 2026 annual general meeting, Amarin shareholders rejected proposals to expand the board’s authority to issue new shares, increase the 2020 Stock Incentive Plan, disapply U.K. pre‑emption rights, and shift to electronic d...
Executive/Board ChangesShareholder Meetings
Amarin Streamlines Board, Updates Director Equity Compensation Plan
Neutral
Mar 27, 2026
On March 25, 2026, Amarin’s board moved to streamline its governance structure by reducing the size of the board from nine to seven directors, following notice from Dr. Paul Cohen and Oliver O’Connor that they would not stand for re-el...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.